Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis
Evaluación de la efectividad y la seguridad del natalizumab en el tratamiento de la esclerosis múltiple remitente recidivante
Leído
2383
Vecesse ha leído el artículo
1022
Total PDF
1361
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 18 | 11 | 29 |
| 2025 5 | 49 | 22 | 71 |
| 2025 4 | 43 | 19 | 62 |
| 2025 3 | 51 | 32 | 83 |
| 2025 2 | 55 | 20 | 75 |
| 2025 1 | 41 | 33 | 74 |
| 2024 12 | 30 | 19 | 49 |
| 2024 11 | 35 | 23 | 58 |
| 2024 10 | 32 | 13 | 45 |
| 2024 9 | 46 | 16 | 62 |
| 2024 8 | 42 | 21 | 63 |
| 2024 7 | 27 | 17 | 44 |
| 2024 6 | 58 | 28 | 86 |
| 2024 5 | 60 | 12 | 72 |
| 2024 4 | 29 | 11 | 40 |
| 2024 3 | 29 | 14 | 43 |
| 2024 2 | 33 | 15 | 48 |
| 2024 1 | 23 | 12 | 35 |
| 2023 12 | 21 | 9 | 30 |
| 2023 11 | 26 | 15 | 41 |
| 2023 10 | 24 | 16 | 40 |
| 2023 9 | 28 | 24 | 52 |
| 2023 8 | 14 | 6 | 20 |
| 2023 7 | 20 | 18 | 38 |
| 2023 6 | 21 | 20 | 41 |
| 2023 5 | 22 | 24 | 46 |
| 2023 4 | 12 | 8 | 20 |
| 2023 3 | 13 | 17 | 30 |
| 2023 2 | 14 | 17 | 31 |
| 2022 1 | 12 | 13 | 25 |
| 2022 12 | 11 | 9 | 20 |
| 2022 11 | 14 | 8 | 22 |
| 2022 10 | 14 | 11 | 25 |
| 2022 9 | 11 | 11 | 22 |
| 2022 8 | 13 | 15 | 28 |
| 2022 7 | 7 | 6 | 13 |
| 2022 6 | 16 | 13 | 29 |
| 2022 5 | 8 | 7 | 15 |
| 2022 4 | 15 | 6 | 21 |
| 2022 3 | 8 | 6 | 14 |
| 2022 2 | 6 | 5 | 11 |
| 2021 1 | 5 | 6 | 11 |
| 2021 12 | 9 | 11 | 20 |
| 2021 11 | 9 | 7 | 16 |
| 2021 10 | 9 | 7 | 16 |
| 2021 9 | 4 | 8 | 12 |
| 2021 8 | 6 | 6 | 12 |
| 2021 7 | 4 | 6 | 10 |
| 2021 6 | 7 | 6 | 13 |
| 2021 5 | 6 | 6 | 12 |
| 2021 4 | 12 | 9 | 21 |
| 2021 3 | 7 | 6 | 13 |
| 2021 2 | 4 | 12 | 16 |
| 2020 1 | 8 | 8 | 16 |
| 2020 12 | 10 | 10 | 20 |
| 2020 11 | 1 | 4 | 5 |
| 2020 10 | 5 | 5 | 10 |
| 2020 9 | 5 | 12 | 17 |
| 2020 8 | 3 | 7 | 10 |
| 2020 7 | 4 | 8 | 12 |
| 2020 6 | 3 | 6 | 9 |
| 2020 5 | 3 | 5 | 8 |
| 2020 4 | 2 | 5 | 7 |
| 2020 3 | 4 | 8 | 12 |
| 2020 2 | 1 | 3 | 4 |
| 2020 1 | 2 | 5 | 7 |
| 2019 12 | 9 | 12 | 21 |
| 2019 11 | 4 | 5 | 9 |
| 2019 10 | 5 | 6 | 11 |
| 2019 9 | 2 | 5 | 7 |
| 2019 8 | 9 | 5 | 14 |
| 2019 7 | 4 | 13 | 17 |
| 2019 6 | 14 | 19 | 33 |
| 2019 5 | 26 | 38 | 64 |
| 2019 4 | 2 | 4 | 6 |
| 2019 3 | 0 | 2 | 2 |
| 2019 2 | 3 | 11 | 14 |
| 2019 1 | 0 | 1 | 1 |
| 2018 12 | 0 | 2 | 2 |
| 2018 11 | 0 | 1 | 1 |
| 2018 10 | 6 | 8 | 14 |
| 2018 9 | 2 | 7 | 9 |
| 2018 8 | 0 | 6 | 6 |
| 2018 7 | 2 | 2 | 4 |
| 2018 6 | 0 | 2 | 2 |
| 2018 5 | 3 | 8 | 11 |
| 2018 4 | 2 | 10 | 12 |
| 2018 3 | 3 | 0 | 3 |
| 2018 2 | 1 | 0 | 1 |
| 2018 1 | 3 | 1 | 4 |
| 2017 12 | 0 | 2 | 2 |
| 2017 11 | 0 | 2 | 2 |
| 2017 10 | 3 | 2 | 5 |
| 2017 9 | 2 | 2 | 4 |
| 2017 8 | 1 | 4 | 5 |
| 2017 7 | 3 | 4 | 7 |
| 2017 6 | 0 | 1 | 1 |
| 2017 5 | 4 | 1 | 5 |
| 2017 3 | 9 | 28 | 37 |
| 2017 2 | 3 | 4 | 7 |
| 2016 1 | 5 | 1 | 6 |
| 2016 12 | 5 | 1 | 6 |
| 2016 11 | 7 | 0 | 7 |
| 2016 10 | 11 | 1 | 12 |
| 2016 9 | 11 | 0 | 11 |
| 2016 8 | 8 | 2 | 10 |
| 2016 7 | 5 | 1 | 6 |
Mostrar todo
